Reports - Oncolytic Virus Immunotherapy Market
HealthcareOncolytic Virus Immunotherapy Market
Oncolytic Virus Immunotherapy Market Valuation and Growth Forecast 2025-2035 by Product Type (Herpes Simplex Virus, Adenovirus, Vaccinia Virus, Vesicular Stomatitis Virus, Other Product Types) by Application (Melanoma, Prostate Cancer, Ovarian Cancer, Lung Cancer, Breast Cancer, Other Applications) by End User (Hospitals, Specialty Clinics, Cancer Research Institutes) by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Industry Leaders Trust Us For Actionable Intelligence
Table of Contents
Chapter 1 Executive Dashboard
1. Strategic Imperatives
Chapter 2 Premium Insights
1. Top 3 Trends to Watch
2. Demand and Supply Trends
3. Top 3 Strategies Followed by Major Players
4. Top 3 Predictions by Vantage Market Research
5. Top Investment Pockets
6. Insights from Primary Respondents
Chapter 3 Global Oncolytic Virus Immunotherapy Market - Segment Analysis
1. Overview
2. Global Oncolytic Virus Immunotherapy Market, 2021 - 2035 (USD Million)
3. Global Oncolytic Virus Immunotherapy Market - by Product Type
3.1. By Herpes Simplex Virus
3.2. By Adenovirus
3.3. By Vaccinia Virus
3.4. By Vesicular Stomatitis Virus
3.5. By Other Product Types
4. Global Oncolytic Virus Immunotherapy Market - by Application
4.1. By Melanoma
4.2. By Prostate Cancer
4.3. By Ovarian Cancer
4.4. By Lung Cancer
4.5. By Breast Cancer
4.6. By Other Applications
5. Global Oncolytic Virus Immunotherapy Market - by End User
5.1. By Hospitals
5.2. By Specialty Clinics
5.3. By Cancer Research Institutes
6. Global Oncolytic Virus Immunotherapy Market - by region
6.1. North America
6.2. Europe
6.3. Asia Pacific
6.4. Latin America
6.5. Middle East & Africa
7. Market comparative analysis
Chapter 4 North America Oncolytic Virus Immunotherapy Market - Segment Analysis
1. Overview
2. North America Oncolytic Virus Immunotherapy Market, 2021 - 2035 (USD Million)
3. North America Oncolytic Virus Immunotherapy Market - by Product Type
3.1. By Herpes Simplex Virus
3.2. By Adenovirus
3.3. By Vaccinia Virus
3.4. By Vesicular Stomatitis Virus
3.5. By Other Product Types
4. North America Oncolytic Virus Immunotherapy Market - by Application
4.1. By Melanoma
4.2. By Prostate Cancer
4.3. By Ovarian Cancer
4.4. By Lung Cancer
4.5. By Breast Cancer
4.6. By Other Applications
5. North America Oncolytic Virus Immunotherapy Market - by End User
5.1. By Hospitals
5.2. By Specialty Clinics
5.3. By Cancer Research Institutes
Chapter 5 Europe Oncolytic Virus Immunotherapy Market - Segment Analysis
1. Overview
2. Europe Oncolytic Virus Immunotherapy Market, 2021 - 2035 (USD Million)
3. Europe Oncolytic Virus Immunotherapy Market - by Product Type
3.1. By Herpes Simplex Virus
3.2. By Adenovirus
3.3. By Vaccinia Virus
3.4. By Vesicular Stomatitis Virus
3.5. By Other Product Types
4. Europe Oncolytic Virus Immunotherapy Market - by Application
4.1. By Melanoma
4.2. By Prostate Cancer
4.3. By Ovarian Cancer
4.4. By Lung Cancer
4.5. By Breast Cancer
4.6. By Other Applications
5. Europe Oncolytic Virus Immunotherapy Market - by End User
5.1. By Hospitals
5.2. By Specialty Clinics
5.3. By Cancer Research Institutes
Chapter 6 Asia Pacific Oncolytic Virus Immunotherapy Market - Segment Analysis
1. Overview
2. Asia Pacific Oncolytic Virus Immunotherapy Market, 2021 - 2035 (USD Million)
3. Asia Pacific Oncolytic Virus Immunotherapy Market - by Product Type
3.1. By Herpes Simplex Virus
3.2. By Adenovirus
3.3. By Vaccinia Virus
3.4. By Vesicular Stomatitis Virus
3.5. By Other Product Types
4. Asia Pacific Oncolytic Virus Immunotherapy Market - by Application
4.1. By Melanoma
4.2. By Prostate Cancer
4.3. By Ovarian Cancer
4.4. By Lung Cancer
4.5. By Breast Cancer
4.6. By Other Applications
5. Asia Pacific Oncolytic Virus Immunotherapy Market - by End User
5.1. By Hospitals
5.2. By Specialty Clinics
5.3. By Cancer Research Institutes
Chapter 7 Latin America Oncolytic Virus Immunotherapy Market - Segment Analysis
1. Overview
2. Latin America Oncolytic Virus Immunotherapy Market, 2021 - 2035 (USD Million)
3. Latin America Oncolytic Virus Immunotherapy Market - by Product Type
3.1. By Herpes Simplex Virus
3.2. By Adenovirus
3.3. By Vaccinia Virus
3.4. By Vesicular Stomatitis Virus
3.5. By Other Product Types
4. Latin America Oncolytic Virus Immunotherapy Market - by Application
4.1. By Melanoma
4.2. By Prostate Cancer
4.3. By Ovarian Cancer
4.4. By Lung Cancer
4.5. By Breast Cancer
4.6. By Other Applications
5. Latin America Oncolytic Virus Immunotherapy Market - by End User
5.1. By Hospitals
5.2. By Specialty Clinics
5.3. By Cancer Research Institutes
Chapter 8 Middle East & Africa Oncolytic Virus Immunotherapy Market - Segment Analysis
1. Overview
2. Middle East & Africa Oncolytic Virus Immunotherapy Market, 2021 - 2035 (USD Million)
3. Middle East & Africa Oncolytic Virus Immunotherapy Market - by Product Type
3.1. By Herpes Simplex Virus
3.2. By Adenovirus
3.3. By Vaccinia Virus
3.4. By Vesicular Stomatitis Virus
3.5. By Other Product Types
4. Middle East & Africa Oncolytic Virus Immunotherapy Market - by Application
4.1. By Melanoma
4.2. By Prostate Cancer
4.3. By Ovarian Cancer
4.4. By Lung Cancer
4.5. By Breast Cancer
4.6. By Other Applications
5. Middle East & Africa Oncolytic Virus Immunotherapy Market - by End User
5.1. By Hospitals
5.2. By Specialty Clinics
5.3. By Cancer Research Institutes
Chapter 9 Key Market Dynamics
1. Introduction
2. Market Drivers
3. Market Restraints
4. Market Opportunities
5. Porter's Five Forces Analysis
6. PEST Analysis
7. Regulatory Landscape
8. Technology Landscape
9. Regional Market Trends
Chapter 10 COVID 19 Impact Analysis
1. Key strategies undertaken by companies to tackle COVID-19
2. Short term dynamics
3. Long term dynamics
Chapter 11 Marketing Strategy Analysis
1. Marketing Channel
2. Direct Marketing
3. Indirect Marketing
4. Marketing Channel Development Trends
Chapter 12 Competitive Landscape
1. Competition Matrix - 2021
2. Company Market Share Analysis - 2021
3. Key Company Activities, 2018 - 2021
4. Strategic Developments - Heat Map Analysis
5. Company Offering Evaluation
6. Company Regional Presence Evaluation
Chapter 13 Company Profiles
1. Sorrento Therapeutics Inc. (U.S.)
2. Merck & Co. Inc. (U.S.)
3. Amgen Inc. (U.S.)
4. Shanghai Sunway Biotech Co. Ltd. (China)
5. Cold Genesys Inc. (U.S.)
6. Oncolytics Biotech Inc. (Canada)
7. Transgene Biotek Ltd. (India)
8. SillaJen Inc. (South Korea)
9. ORYX GmbH & Co. KG (Germany)
10. Viralytics Ltd. (Australia)
Chapter 14 Key Primary Respondents - VERBATIM
Chapter 15 Discussion Guide
Chapter 16 Customization Offered
Chapter 17 Annexure
Chapter 18 List of Figures
Chapter 19 List of Tables
Chapter 20 List of Abbreviations
FAQ‘s
Related Reports
Contact
Toll Free Number+1 (877) 462-2282
© 2025 Vantage Market Research. All right reserved
Secured By